Menu
Enrolling by invitation NCT07041372

Cerebral Atherosclerosis Research With Positron Emission Tomography

Observational Cerebral Infarction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: FDG-PET.
Who it may be relevant to
Registry conditions: Cerebral Infarction. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are: * Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors? * Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients. Participants will: * Undergo whole-body FDG PET once their neurological status has stabilized after stroke. * Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day. * Maintain regular clinic visits for up to 24 months following the index stroke

Interventions

  • Diagnostic test FDG-PET
    The participants undergo whole-body FDG PET once their neurological status has stabilized after stroke.

Primary outcome measures

  • Vascular events [Time frame: up to 24 months after index stroke]
Secondary outcome measures (1)
  • overall vascular events [Time frame: up to 24 months after index stroke]

Eligibility criteria

Inclusion criteria

  • acute ischemic stroke patients who admitted within seven days after symptom onset

Exclusion criteria

  • Patients with unstable vital signs or neurological symptoms
  • Patients with estimated glomerular filtration rate less than 30ml/min
  • Patients with uncontrolled diabetes requiring persistent insulin injection
  • During pregnancy or while breastfeeding
  • Patients with impaired consent capacity
  • Patients with diagnosed/treatment for dementia
  • Patients undergoing treatment for malignant tumors or serious autoimmune diseases

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

South Korea · 1 center
  • Seoul National University Hospital — Seoul

Identifiers

NCT: NCT07041372 · CARPET

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗